INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Oppenheimer Reiterates Outperform Rating on Inovio Pharmaceuticals (INO)
May 14, 2024 10:08 AM EDTOppenheimer analyst Hartaj Singh reiterated an Outperform rating and $40.00 price target on Inovio Pharmaceuticals (NASDAQ: INO)
The analyst comments "
Inovio Pharmaceuticals (INO) reported 1Q24 financial updates and business highlights on 05/13. The company continues on track to initiate the RRP confirmatory trial of... More
